Brain iron: A promising noninvasive biomarker of attention-deficit/hyperactivity disorder that warrants further investigation

Biomarkers in Medicine

Volumn 9, Issue 5, 2015, Pages 403-406

  Adisetiyo, Vitria ^a   Helpern, Joseph A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

ADHD; Biomarker; Brain iron; Dopamine; MFC; MRI; Psychostimulants; Quantitative susceptibility mapping; Relaxation rates

Indexed keywords

BIOLOGICAL MARKER; IRON;

ATTENTION DEFICIT DISORDER; BRAIN LEVEL; CLINICAL ASSESSMENT; DIAGNOSTIC ERROR; DOPAMINERGIC SYSTEM; HUMAN; IRON BLOOD LEVEL; IRON BRAIN LEVEL; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; BLOOD; BRAIN; METABOLISM; PATHOLOGY;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOMARKERS; BRAIN; HUMANS; IRON;

EID: 84929576384     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.9     Document Type: Review

References (28)

1. Cortese S, Castellanos FX. Neuroimaging of attentiondeficit/hyperactivity disorder: current neuroscience-informed perspectives for clinicians. Curr. Psychiatry Rep. 14(5), 568-578 (2012).
2. Cortese S, Angriman M, Lecendreux M, Konofal E. Iron and attention deficit/hyperactivity disorder: what is the empirical evidence so far? A systematic review of the literature. Expert Rev. Neurother. 12(10), 1227-1240 (2012).
3. McCann JC, Ames BN. An overview of evidence for a causal relation between iron deficiency during development and deficits in cognitive or behavioral function. Am. J. Clin. Nutr. 85(4), 931-945 (2007).
4. Donfrancesco R, Parisi P, Vanacore N, Martines F, Sargentini V, Cortese S. Iron and ADHD: time to move beyond serum ferritin levels. J. Atten. Disord. 17(4), 347-357 (2013).
5. Adisetiyo V, Jensen JH, Tabesh A et al. Multimodal MR imaging of brain iron in attention deficit hyperactivity disorder: a noninvasive biomarker that responds to psychostimulant treatment? Radiology 272(2), 524-532 (2014).
6. Simpson IA, Ponnuru P, Klinger ME et al. A novel model for brain iron uptake: introducing the concept of regulation. J. Cereb. Blood Flow Metab. 35(1), 48-57 (2015).
7. Lozoff B. Early iron deficiency has brain and behavior effects consistent with dopaminergic dysfunction. J. Nutr. 141(4), 740S-746S (2011).
8. Beard JL, Connor JR. Iron status and neural functioning. Annu. Rev. Nutr. 23, 41-58 (2003).
9. Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys. 508(1), 1-12 (2011).
10. Ramsey AJ, Hillas PJ, Fitzpatrick PF. Characterization of the active site iron in tyrosine hydroxylase. Redox states of the iron. J. Biol. Chem. 271(40), 24395-24400 (1996).
11. Hallgren B, Sourander P. The effect of age on the nonhaemin iron in the human brain. J. Neurochem. 3(1), 41-51 (1958).
12. Mohamed WM, Unger EL, Kambhampati SK, Jones BC. Methylphenidate improves cognitive deficits produced by infantile iron deficiency in rats. Behav. Brain Res. 216(1), 146-152 (2011).
13. Rizzo G, Tonon C, Manners D, Testa C, Lodi R. Imaging brain functional and metabolic changes in restless legs syndrome. Curr. Neurol. Neurosci. Rep. 13(9), 372 (2013).
14. Dusek P, Dezortova M, Wuerfel J. Imaging of iron. Int. Rev. Neurobiol. 110, 195-239 (2013).
15. Ide S, Kakeda S, Ueda I et al. Internal structures of the globus pallidus in patients with Parkinson's disease: evaluation with quantitative susceptibility mapping (QSM). Eur. Radiol. doi:10.1007/s00330-014-3472-7 (2014) (Epub ahead of print).
16. Dumas EM, Versluis MJ, van den Bogaard SJ et al. Elevated brain iron is independent from atrophy in Huntington's disease. Neuroimage 61(3), 558-564 (2012).
17. Cortese S, Azoulay R, Castellanos FX et al. Brain iron levels in attention-deficit/hyperactivity disorder: a pilot MRI study. World J. Biol. Psychiatry 13(3), 223-231 (2012).
18. Adisetiyo V, Tabesh A, Di Martino A et al. Attention-deficit/hyperactivity disorder without comorbidity is associated with distinct atypical patterns of cerebral microstructural development. Hum. Brain Mapp. 35(5), 2148-2162 (2014).
19. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol. Psychiatry 69(12), e145-e157 (2011).
20. Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol. Psychiatry 57(11), 1410-1415 (2005).
21. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A metaanalysis. Am. J. Psychiatry 169(3), 264-272 (2012).
22. Morton WA, Stockton GG. Methylphenidate abuse and psychiatric side effects. Prim. Care. Companion J. Clin. Psychiatry 2(5), 159-164 (2000).
23. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adolesc. Psychiatry 35(4), 409-432 (1996).
24. Schwarz A. Drowned in a stream of prescriptions. New York Times, 3 February 2013.
25. Visser SN, Danielson ML, Bitsko RH et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J. Am. Acad. Child Adolesc. Psychiatry 53(1), 34-46.e2 (2014).
26. Schwarz A. Attention disorder or not, pills to help in school. New York Times, 9 October 2012.
27. Groenman AP, Oosterlaan J, Rommelse NN et al. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. Br. J. Psychiatry 203(2), 112-119 (2013).
28. Newcorn JH, Halperin JM, Jensen PS et al. Symptom profiles in children with ADHD: effects of comorbidity and gender. J. Am. Acad. Child Adolesc. Psychiatry 40(2), 137-146 (2001).